Homologous recombination deficiency (HRD) arises when defects in DNA repair pathways occur, leading to genomic instability.
HRD status is an emerging therapeutic biomarker; NGS assays that measure it can be used to stratify ovarian and breast cancer patients and determine eligibility for clinical trials, PARP inhibitors, and platinum-based therapies. Seraseq FFPE HRD reference materials were developed to cover a range of genomic instability scores to help NGS HRD assay validation and development.
This scientific poster from LGC SeraCare discusses a multi-site evaluation across various platforms of high-positive, low-positive, and negative HRD reference materials.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences